Does TRICARE Cover Wegovy? Plan-by-Plan Coverage, PA Rules, and 2026 Costs
By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers.
Published: · Last reviewed:
Reviewed quarterly or when TRICARE updates its Wegovy policies.
Some links on this page are affiliate links. We may earn a commission if you choose a featured provider, at no extra cost to you. Our coverage facts come from TRICARE.mil, Express Scripts, the current Wegovy PA form, the DHA 2026 pharmacy cost schedule, and Novo Nordisk. We do not change our recommendations based on payouts.
The short answer
Does TRICARE cover Wegovy? Yes — if you have TRICARE Prime, TRICARE Select, or one of the premium-based plans (TRICARE Reserve Select, Retired Reserve, Young Adult, CHCBP, USFHP), and your prescriber gets prior authorization approved. No — if you have TRICARE For Life or direct-care-only access. Weight-loss GLP-1 coverage ended for those groups on August 31, 2025 under a Defense Health Agency regulatory-controls policy. Active-duty service members pay $0 at every pharmacy channel when the PA is approved.
Here's the part nobody tells you upfront: even on the right plan, the prior-authorization form has six practical gates — provider type, indication, age/product, BMI plus comorbidity, six months of documented lifestyle work, and step therapy or an exception — plus three safety stops. Miss any one and the form ends in "coverage not approved." Most documentation denials are fixable. Plan exclusions aren't. This guide shows you which is which before you waste an appointment.
For a broader view of every GLP-1 on TRICARE, see our TRICARE GLP-1 coverage hub.
Your situation in 15 seconds
| Your plan | Wegovy covered? | What to do next |
|---|---|---|
| TRICARE Prime, Prime Remote, USFHP | Yes, with approved PA | Bring our PA checklist to your PCM |
| TRICARE Select, Reserve Select, Retired Reserve, Young Adult, CHCBP | Yes, with approved PA | Same path — but verify your plan category isn't filed as "Other" |
| TRICARE For Life | No (weight loss) | See the TFL section below |
| Direct-care-only, NATO, Partnership for Peace | No (weight loss) | See the cash-pay verification table below |
| You have type 2 diabetes | Wegovy is the wrong drug | TRICARE covers Ozempic, Mounjaro, Trulicity, or Victoza for diabetes — ask your provider |
| You have moderate-to-severe obstructive sleep apnea | Zepbound, not Wegovy | The current TRICARE PA form routes OSA to Zepbound — ask your provider about the Zepbound OSA route |
Not sure which path applies to you?
Our free 60-second matching quiz accounts for your TRICARE plan, BMI, comorbidities, step-therapy history, and whether you want injection or pill — and tells you the realistic best path.
Take the 60-Second GLP-1 Match Quiz →Does TRICARE Cover Wegovy in 2026?
TRICARE covers Wegovy for adults and adolescents 12–17 with obesity when you have an eligible plan, meet clinical criteria, and your prescriber submits prior authorization to Express Scripts. The eligible plans are TRICARE Prime, TRICARE Select, and the premium-based plans (Reserve Select, Retired Reserve, Young Adult, CHCBP, USFHP). TRICARE For Life and direct-care-only beneficiaries lost weight-loss GLP-1 coverage on August 31, 2025.
Three things matter most:
- 1Your plan category. Prime, Select, and the premium-based plans can pursue coverage. TRICARE For Life and a few smaller groups cannot, regardless of the strength of your medical case.
- 2Prior authorization. Even on the right plan, no Wegovy gets paid without an approved PA. Your prescriber fills out the form — you can't submit it yourself.
- 3Your prescriber. The current TRICARE PA form asks whether the prescriber is an MTF clinician or a TRICARE Network provider who has billed TRICARE for professional services to assess you and develop a treatment plan. A cash-pay telehealth prescription on its own does not unlock TRICARE coverage.
TRICARE Wegovy Coverage Matrix (May 2026)
Every TRICARE plan category mapped to Wegovy coverage status, prior authorization requirements, and 2026 copay tier. Assembled from the TRICARE.mil Wegovy/Ozempic/Mounjaro FAQ, the TRICARE Weight Loss Products policy page, the Express Scripts TRICARE pharmacy FAQ, the current Wegovy/Zepbound PA form, and the TRICARE Pharmacy Costs page updated April 10, 2026.
| TRICARE plan | Wegovy injection (0.25–2.4 mg) | Wegovy HD / Oral pill | Pediatric (ages 12–17) | PA required? | 2026 cost (90-day Home Delivery) |
|---|---|---|---|---|---|
| TRICARE Prime / Prime Remote | Covered | Live formulary check required | Covered | Yes + step therapy (adults) | $0 active duty / $0 Prime Remote / $44 brand-formulary / $85 non-formulary |
| TRICARE Select | Covered | Live formulary check required | Covered | Yes + step therapy (adults) | $44 brand-formulary / $85 non-formulary |
| TRICARE Reserve Select | Covered (premium-based) | Live formulary check required | Covered | Yes + step therapy (adults) | $44 brand-formulary / $85 non-formulary |
| TRICARE Retired Reserve | Covered (premium-based) | Live formulary check required | Covered | Yes + step therapy (adults) | $44 brand-formulary / $85 non-formulary |
| TRICARE Young Adult | Covered (premium-based) | Live formulary check required | N/A (18+) | Yes + step therapy (adults) | $44 brand-formulary / $85 non-formulary |
| CHCBP | Covered (premium-based) | Live formulary check required | Covered | Yes + step therapy (adults) | $44 brand-formulary / $85 non-formulary |
| USFHP | Covered through USFHP designated provider | Live formulary check required | Covered | Yes | Varies by USFHP region — verify with your designated provider |
| Medically retired sponsors / certain survivors | Covered (same PA process) | Live formulary check required | Covered | Yes + step therapy (adults) | $20 brand-formulary / $49 non-formulary (Home Delivery) |
| TRICARE For Life | Not covered for weight loss since 8/31/2025 | Not covered | Not covered | N/A | Cash-pay only — see TFL section below |
| Direct-care-only / NATO / Partnership for Peace | Not covered through TRICARE Pharmacy Program | Not covered | Not covered | N/A | Cash-pay only |
Pediatric note: The pediatric pathway does not include the adult three-month generic step-therapy gate. Adolescents 12–17 proceed from BMI-percentile and lifestyle documentation directly to safety screening.
Wegovy HD (7.2 mg, FDA-approved March 19, 2026) and the Wegovy oral pill have product-specific formulary status — verify in the live TRICARE Formulary Search Tool before your appointment.
The 6 Denial Gates of TRICARE's Wegovy PA
TRICARE's Wegovy prior-authorization form, processed by Express Scripts, has multiple numbered questions with branching paths. Those branches collapse into six practical denial gates plus three safety stops. Miss any one and the form ends in “coverage not approved.”
Plan and provider
The form asks two things up front. First, what TRICARE plan are you under? Prime, Select, and the premium-based plans proceed. TFL and direct-care-only do not.
Second, is the prescriber an MTF clinician or a TRICARE Network provider who has billed TRICARE for services to assess you and build a treatment plan? Cash-pay telehealth alone doesn't qualify.
Indication
Wegovy proceeds for weight management. The form ends in “coverage not approved” if it's submitted with the wrong indication. Two specific traps:
- ✗Diabetes: Wegovy is not TRICARE's diabetes path. Ozempic, Mounjaro, Trulicity, or Victoza is the diabetes path.
- ✗Obstructive sleep apnea: The current combined Wegovy/Zepbound PA form routes OSA to Zepbound, not Wegovy. Wegovy doesn't have an FDA-approved OSA indication — a Wegovy submission for OSA is denied at this gate.
Age and product
- ✗Under 12: Stop. Not covered.
- ✓Ages 12–17: Pediatric pathway opens for Wegovy injection only. The form explicitly blocks Wegovy tablets and Zepbound at this age.
- ✓18 and older: Adult pathway opens for Wegovy injection. Wegovy HD and oral tablet product-level status must be confirmed in the live TRICARE Formulary Search Tool.
BMI plus comorbidity
For adolescents 12–17, the form requires BMI at or above the 95th percentile for age and sex, documented in the medical record.
For adults:
| Adult BMI | What happens on the PA form |
|---|---|
| Under 27 | Stop. Not covered. |
| 27 to 29.9 | Proceeds only if you have at least one listed weight-related comorbidity |
| 30 and above | Proceeds |
Qualifying comorbidities for the BMI 27–29.9 path:
If your BMI is 27–29.9 with a qualifying comorbidity, that comorbidity must be in your medical record before the PA goes in. Saying it in the visit isn't enough.
Six months of documented lifestyle modification
The form asks your prescriber to attest that you've been engaged in lifestyle modification — diet and exercise — for at least six months, that it failed to produce the weight loss needed, and that you'll remain engaged during therapy.
What counts
- • Diet and physical-activity record in your medical record
- • Weight-management program participation (commercial, military, or clinical)
- • Nutritionist or dietitian visit log
- • Provider notes describing lifestyle attempts and weight trajectory
What does NOT count
- • Telling the doctor at the visit that you "tried"
- • Verbal history without chart documentation
- • Undocumented commercial diet programs
Step therapy — adult path only (most common denial)
The PA form asks whether you've completed a three-month trial of one of these four generic medications, with the trial failing to produce at least 5% baseline weight loss:
⚠ Important
Only those four drugs count. Some guides reference Contrave, Qsymia, or Saxenda as step drugs. They are not on the current TRICARE form. A Qsymia or Contrave trial does not satisfy this gate.
Exception path: If you can't take any of the four listed step drugs, your prescriber can document a contraindication (arrhythmias, coronary artery disease, heart failure, recent stroke, or uncontrolled hypertension) or an adverse reaction to one of the listed drugs.
The pediatric pathway does not have this step-therapy gate.
The three safety stops — automatic denial
- ✗Pregnancy. Wegovy is contraindicated. Talk to your clinician about non-Wegovy paths.
- ✗Concurrent use of another GLP-1 receptor agonist. Wegovy labeling says not to use Wegovy with other semaglutide-containing products or other GLP-1 receptor agonists.
- ✗Personal or family history of medullary thyroid carcinoma (MTC) or MEN2. This is an FDA-labeled contraindication for all semaglutide products — not a TRICARE policy quirk.
What Wegovy Actually Costs You on TRICARE in 2026
If your prior authorization is approved, Wegovy on TRICARE in 2026 costs $0 at a military treatment facility pharmacy when available, $44 for a 90-day brand-formulary supply through TRICARE Pharmacy Home Delivery, or $85 for a 90-day non-formulary Home Delivery supply. Network retail pharmacies cost $48 (30-day brand-formulary) or $85 (30-day non-formulary). Active-duty service members pay $0 at every pharmacy type.
The 2026 cost matrix
| Pharmacy channel | Active duty | Prime Remote | Medically retired / certain survivors | All other non-active-duty (brand-formulary) | Non-formulary |
|---|---|---|---|---|---|
| Military pharmacy (MTF), up to 90 days | $0 | $0 | $0 | $0 | Generally not stocked without medical-necessity auth |
| TRICARE Pharmacy Home Delivery, 90 days | $0 | $0 | $20 brand / $49 non-formulary | $44 | $85 |
| Network retail pharmacy, 30 days | $0 | $0 | $24 brand / $50 non-formulary | $48 | $85 |
| Non-network retail | Pay upfront, file claim — all beneficiary categories | ||||
Why Home Delivery beats every other pharmacy choice for most beneficiaries
The math for most non-active-duty beneficiaries: $44 for 90 days = roughly $15/month effective. That is dramatically lower than the standard $25/month floor on commercial Wegovy savings offers and the $349/month cash-pay price published by NovoCare. One of the lowest verified out-of-pocket prices for FDA-approved Wegovy available in the United States today — if TRICARE approves the PA and the fill is billed through the right pharmacy channel.
Non-formulary vs formulary: nearly double the cost
If your PA is approved and the drug is billed at the non-formulary tier instead of the brand-name formulary tier, your 90-day cost is $85 instead of $44. Two things can trigger non-formulary billing: a Wegovy SKU not yet formally added to the formulary (which can happen with newer products like Wegovy HD or oral tablets), or a documentation issue at PA submission. If you see "non-formulary" on your approval letter, ask Express Scripts whether a medical-necessity request is available for your fill channel.
How to Verify Wegovy's Live TRICARE Formulary Status Before Your Appointment
Open the TRICARE Formulary Search Tool the day of your appointment. Confirm three things: the exact Wegovy product form your prescriber plans to write (injection, tablet, or HD), the current formulary category for that product, and the current revision date of the PA form. Wegovy injection, Wegovy tablets, and Wegovy HD can have different product-level status, and the formulary updates quarterly.
What to check in the formulary tool:
- • Product: Wegovy injection (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, or HD 7.2 mg), Wegovy tablets (1.5 mg, 4 mg, 9 mg, 25 mg), or both
- • Formulary status: Brand-name formulary, non-formulary, or excluded
- • PA form: Pull the current PDF and note the revision date at the bottom — forms are updated periodically
- • Pharmacy channels: Some non-formulary drugs are only covered through Home Delivery or military pharmacies
Direct link to the Express Scripts–operated TRICARE Formulary Search Tool. We don't earn anything from this.
Does TRICARE Cover Wegovy HD, the Wegovy Pill, or Pediatric Wegovy?
Wegovy HD 7.2 mg on TRICARE
Wegovy HD is a higher-dose pen — 7.2 mg of semaglutide once weekly instead of the standard 2.4 mg. The FDA approved it on March 19, 2026 for weight loss and long-term maintenance of weight loss. In a 72-week late-stage trial, participants on the 7.2 mg dose lost an average of 20.7% of their body weight, compared with 17.5% for the 2.4 mg dose (Reuters reporting on the STEP UP trial).
Current TRICARE status: Verify in the TRICARE Formulary Search Tool. If Wegovy HD is approved as a non-formulary medical necessity, the Home Delivery copay would be $85 for 90 days under standard non-active-duty pricing.
Wegovy oral tablets on TRICARE
The Wegovy oral tablet is the first FDA-approved oral semaglutide for weight management. Doses are 1.5 mg, 4 mg, 9 mg, and 25 mg. The Express Scripts PA form is titled for semaglutide injection and tablets, but pediatric coverage is explicitly limited to the injection. Adult tablet coverage must be verified in the live TRICARE Formulary Search Tool.
If you're needle-averse, the oral pill might be the version you actually want — but confirm formulary status first and walk in with a backup plan (the injection) if the tablets aren't approved at your formulary tier.
Pediatric Wegovy (ages 12–17) on TRICARE
Pediatric pathway requirements:
- · Wegovy injection only — not tablets, not Zepbound
- · BMI at or above the 95th percentile for age and sex, documented in the medical record
- · Six months of documented behavioral modification and dietary restriction before the PA
- · Provider attestation that patient and family will remain engaged during therapy
- · No three-month generic step-therapy gate — that requirement only applies to adults
- · Renewal threshold: at least 4% baseline weight loss (vs 5% for adults)
If you're a parent of a teen who might qualify, the path exists. The hard part is the six-month documented lifestyle record — start that with your pediatrician now, not after a denial.
If You Have TRICARE For Life: What Changed and What You Can Do Now
TRICARE For Life beneficiaries lost weight-loss GLP-1 coverage on August 31, 2025 under what the Defense Health Agency called “existing regulatory controls.” Wegovy, Zepbound, Saxenda, Qsymia, Phentermine, and Contrave were all affected for weight-loss use. Even previously approved prior authorizations no longer pay for weight-loss indications.
We want to be straight with you: this was a real blow. Many TFL beneficiaries were on Wegovy for months — losing real weight, reducing real comorbidities — and got cut off mid-treatment. The Military Officers Association of America (MOAA) has been pushing back hard. In March 2026, MOAA reported that Col. Derence Fivehouse, USAF (Ret.), filed a legal case seeking to reverse the TFL GLP-1 coverage change. The policy remains in effect while that process plays out.
“Zepbound has made such a great difference in my life that I can't imagine going back.”
Path 1: Medicare GLP-1 Bridge (best near-term option if you have Part D)
If you're a TFL beneficiary enrolled in an eligible Medicare Part D plan, the Medicare GLP-1 Bridge program is the cheapest legitimate path back to weight-loss GLP-1 coverage. The Bridge runs from July 1, 2026 through December 31, 2027. CMS lists Foundayo, Wegovy injection, Wegovy tablets, and Zepbound KwikPen as eligible weight-management products. Pharmacies collect a $50 copay at fill for eligible beneficiaries who meet the Bridge's PA criteria.
- • The Bridge is not a blanket Part D weight-loss benefit — it has its own PA criteria
- • Does not apply when the drug is coverable under your basic Part D benefit for a different indication
Path 2: Wegovy's cardiovascular-risk indication through Part D
Wegovy has an FDA-approved indication for reducing cardiovascular risk in adults with known heart disease and obesity or overweight. If that applies to you, your Part D plan may cover Wegovy for that indication through its standard formulary or an exception process — separate from the GLP-1 Bridge. This is the most direct path to Part D coverage for TFL beneficiaries with established heart disease (prior heart attack, stroke, or peripheral artery disease).
Path 3: A verified cash-pay telehealth route
If you don't have Part D, don't qualify for the Bridge, and don't have established cardiovascular disease, your only remaining FDA-approved path is cash-pay. But this is where it gets complicated, and where most other guides oversimplify the answer.
The Wegovy savings card and Novo Nordisk's published self-pay offer pricing both exclude government-program beneficiaries — including TRICARE — in their published terms. Don't pay anyone for Wegovy on a cash-pay basis until you've confirmed your TRICARE eligibility for that specific product with that specific provider.
Cash-Pay Options: Provider-Stated vs Terms-Verified
The cash-pay landscape for TRICARE/TFL beneficiaries seeking Wegovy is more restricted than most public-facing provider pages make it sound. Use this before paying anyone.
| Provider/program | What the public page says | What offer terms say about TRICARE | Safe action |
|---|---|---|---|
| Wegovy Savings Card (Novo Nordisk) | “Pay as little as $25/month with the card” | Terms explicitly exclude TRICARE, Medicare, Medicaid, VA, and DoD beneficiaries — including when beneficiaries elect to self-pay | Not available to TRICARE beneficiaries. Don't try to use it. |
| NovoCare direct self-pay (Wegovy) | $349/month standard, $399/month HD, $149–$299/month tablets | Government-program beneficiaries may not be eligible for self-pay offer pricing even if they elect to go outside insurance | Verify directly with NovoCare before assuming offer price is available. Call 1-888-793-1218. |
| Ro Body membership | $39 first month, $149/month ongoing, or ~$74/month with annual plan | TRICARE beneficiaries may join and pay cash for certain cash-pay medication options — but Wegovy specifically must be confirmed | Confirm Wegovy is on the cash-pay list for TRICARE users before paying for membership |
| Sesame Care weight-loss program | Online weight-loss program pricing available regardless of insurance | Terms of Service may exclude federal-program beneficiaries from specific offers | Confirm federal-program eligibility for the specific service/promotion before paying |
Two phone calls before you sign up for anything:
- 1. Call NovoCare at 1-888-793-1218 and ask: “I have [TRICARE / TFL / direct-care-only]. Can I use your self-pay offer pricing for Wegovy?”
- 2. Call Ro support (in the Ro app or via Ro.co) and ask: “I have TRICARE / TFL. Is Wegovy on the cash-pay medication list I can access through Body membership?”
Ro Body (verify TRICARE eligibility first)
$39 first month, $149/month ongoing, or ~$74/month annual. Government-insurance coordination not available. Confirm Wegovy cash-pay availability for TRICARE users directly with Ro before signing up.
Check Ro's Cash-Pay Options → (sponsored affiliate link, opens in a new tab)Sponsored link. We may earn commission. Coverage findings are independent of affiliate relationships.
Sesame Care (verify eligibility first)
Confirm federal-program eligibility for the specific offer before paying. Program pricing is public but Terms of Service may restrict some offers for federal-program beneficiaries.
Check Sesame Care Options → (sponsored affiliate link, opens in a new tab)Sponsored link. We may earn commission. Coverage findings are independent of affiliate relationships.
Why Your TRICARE Wegovy PA Got Denied (And What's Fixable)
TRICARE Wegovy denials fall into two categories: fixable documentation problems and true coverage exclusions. Sort which category yours falls into before asking your provider to resubmit.
| Denial reason | Category | What to do |
|---|---|---|
| TRICARE For Life or excluded group | Plan exclusion (not fixable) | Move to a verified cash-pay path or Part D / Bridge path. Stop chasing a PA that can't be approved. |
| Provider checked “Other” plan category (common with Reserve Select) | Documentation problem (fixable) | Call Express Scripts to verify how your enrollment should be coded, then resubmit |
| Prescriber not MTF or TRICARE Network | Documentation problem (fixable) | Switch to a TRICARE Network or MTF provider |
| BMI below 27, or 27–29.9 with no documented comorbidity | Documentation gap (fixable if comorbidity is real) | Get the comorbidity documented in your chart and resubmit |
| No six-month behavioral/lifestyle modification record | Documentation gap (most common adult denial) | Document a lifestyle program with your provider; resubmit after the documentation period |
| No step-therapy trial of phentermine, benzphetamine, diethylpropion, or phendimetrazine | Documentation gap (fixable) | Complete a three-month trial OR have your provider document a contraindication or adverse reaction |
| Form submitted for diabetes indication | Wrong path | Wegovy is not TRICARE's diabetes drug — ask about Ozempic, Mounjaro, Trulicity, or Victoza |
| Form submitted for OSA indication | Wrong drug | TRICARE routes OSA to Zepbound, not Wegovy. Ask about Zepbound. |
| Pregnancy | Safety stop (not fixable) | Wegovy is contraindicated. Talk to your clinician about non-GLP-1 options |
| Concurrent GLP-1 use | Safety stop / fixable with washout | Discontinue the other GLP-1 first; resubmit after a clean washout |
| Personal/family MTC or MEN2 history | FDA-label contraindication (not fixable) | Wegovy is not an option through any path. Discuss alternatives with your clinician. |
The Reserve Select trap
“The Tricare.mil website says that TRS is one of the Premium paid plans that covers it, however the PA form only listed Tricare Prime and Tricare Select.”
TRICARE Reserve Select is an eligible plan for Wegovy coverage. The confusion happens because some PA workflows collapse plan categories or default to “Other,” which can flag a denial that looks like a true exclusion.
Do not have your provider check a false plan category to “fix” this — that's fraud and can blow up later. The right move:
- 1. Call Express Scripts at 1-877-363-1303 before the PA is submitted
- 2. Ask how Reserve Select should be represented on the current PA workflow
- 3. Have your provider submit using whatever Express Scripts confirms
The “coupon won't work” trap
“I'm apparently not eligible for the copay card because I have TRICARE.”
This isn't a denial of coverage — it's the savings card that's blocked, not your TRICARE Wegovy coverage itself. Federal-program beneficiaries are excluded from the Wegovy savings card by Novo Nordisk's published offer terms. See the savings-card section below for more.
How to Get TRICARE Wegovy Approved on the First Try
The fastest path to a clean approval: confirm your plan category, book with a TRICARE Network or MTF provider, walk in with documented BMI/comorbidity/lifestyle/step-therapy history, and have the provider submit the current PA form to Express Scripts with every numbered question answered. Incomplete packets bounce back as “more information required,” which adds weeks to your wait.
Confirm your plan category on milConnect
Log in at milConnect.dmdc.osd.mil and pull your DEERS enrollment record. Don't guess. Write down the exact plan name as it appears.
Book with a TRICARE Network or MTF provider
The PA form asks whether the prescriber is an MTF clinician or a TRICARE Network provider who has billed TRICARE for professional services to assess you and develop a treatment plan. Your primary care manager at the base, or a TRICARE Network family-medicine or obesity-medicine provider, is the right call. A cash-pay telehealth doctor who just writes the script doesn't qualify.
Pull the current PA form from the live formulary tool
Search 'Wegovy' in the TRICARE Formulary Search Tool the morning of your appointment. Pull the current PA form. Verify the revision date on the PDF. Confirm Wegovy's current formulary category.
Bring the complete documentation packet
Your TRICARE sponsor ID, plan name from milConnect, current height/weight/BMI, baseline weight from six-plus months ago, obesity/overweight diagnosis, comorbidity documentation, six-month behavioral/dietary modification record, prior step-therapy drug history with dates and weight response, any contraindication documentation, pregnancy status, current GLP-1 (if any), personal/family thyroid cancer/MEN2 history, and preferred pharmacy channel.
Have your provider submit the PA to Express Scripts
The form has fax, mail, and electronic submission options. Most provider offices fax. Complete packets get faster decisions than incomplete ones.
Plan your renewal from day one
Adult renewal requires at least 5% baseline body-weight loss after full dosage titration to 2.4 mg, plus continued behavioral modification. Pediatric renewal requires 4% baseline weight loss. Initial approval is for 12 months — set a reminder at month 10 to start your renewal documentation.
Active Duty: The Fitness, Command, and MTF Angle
Active-duty service members pay $0 for Wegovy at every TRICARE pharmacy channel when the PA is approved. But Military Department–specific weight-management policies layer on top of the standard TRICARE PA. Your provider must still submit the form to Express Scripts even if you'll fill at an MTF.
Will my command see this on my record?
Wegovy prescription is a medical record matter handled like any other prescription through the TRICARE pharmacy benefit. It's not automatically flagged to command. Your medical record is governed by the same confidentiality rules as any other clinical record. However, if Wegovy is part of an official weight-management program tied to fitness standards, that program participation may be visible to your unit medical team.
Will my MTF pharmacy actually stock Wegovy?
Not always. Military pharmacies generally don't stock non-formulary drugs without medical-necessity authorization. Call your MTF pharmacy before walking in to confirm they have it. If they don't, TRICARE Pharmacy Home Delivery is your $0 backup as an active-duty member.
Does my service have its own weight-management program rules?
Yes. Each service (Army, Navy/Marines, Air Force, Space Force, Coast Guard) has its own weight-management program with specific participation and documentation requirements. The TRICARE PA is required for the medication, but your service's program may require additional steps — body composition assessments, fitness leadership notification, command medical concurrence. Ask your unit medical team how Wegovy fits into your service's program before you start.
The form must still be submitted, even at an MTF
Even when coverage is being filled on base, Express Scripts must still receive the PA submission. Don't let an MTF pharmacist tell you to skip the form because “we have it on base.” Submit through Express Scripts first.
How to Appeal a TRICARE Wegovy Denial
If TRICARE denies your Wegovy prior authorization, TRICARE's pharmacy appeal process requires a written, signed appeal that explains why you disagree, includes a copy of the claim decision, and is postmarked or received by Express Scripts within 90 calendar days of the decision date. Follow the specific submission instructions on your denial letter.
What to put in your appeal
- 1
Address each reason on the denial letter specifically. Read it carefully — it tells you which gate failed. Don't write a general complaint; address the specific issue.
- 2Add the missing documentation. The most common appeal-winning additions:
- A specialist letter (endocrinologist, obesity-medicine, cardiologist) supporting medical necessity
- A more thorough six-month lifestyle modification record
- Documentation of a step-therapy trial not included in the original PA
- A contraindication letter from your provider if step therapy isn't appropriate
- 3
Have your provider sign or co-sign the appeal.
- 4
Submit per the instructions on your denial letter. Express Scripts publishes current submission addresses and fax numbers on the denial letter and on the TRICARE Pharmacy Appeals page.
If the appeal fails:
- • Check whether you're in a covered plan category — some denials look like clinical denials but are actually plan exclusions
- • Talk to your installation's beneficiary counseling and assistance coordinator (BCAC)
- • For TFL beneficiaries: stop appealing the weight-loss path and switch to the Medicare GLP-1 Bridge, the Part D cardiovascular-risk path, or a verified cash-pay route
Wegovy vs Zepbound on TRICARE (And the OSA Trap)
TRICARE covers both Wegovy and Zepbound for weight management under the same combined prior-authorization form, with identical BMI and step-therapy requirements for adults. Zepbound has one major advantage: a separate pathway for moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥30, AHI ≥15) that doesn't require the step-therapy phentermine trial. Wegovy doesn't have an FDA-approved OSA indication and cannot use that route.
The OSA trap — what happens:
A TRICARE beneficiary has obesity and a documented sleep-apnea diagnosis. Their doctor submits a PA for Wegovy with OSA as the indication. The form ends in “coverage not approved.”
Why? The FDA approved Wegovy for weight management and cardiovascular-risk reduction — not for OSA. The current TRICARE PA form routes OSA requests to Zepbound, which has an FDA-approved OSA indication.
If OSA is your primary qualifying condition
Ask your provider about Zepbound, not Wegovy. Submit under the OSA pathway.
If OSA is one of several comorbidities and BMI ≥30
Wegovy is fine. Submit under the weight-management path and list OSA as one qualifying comorbidity, not the primary indication.
| Feature | Wegovy (semaglutide) | Zepbound (tirzepatide) |
|---|---|---|
| Adult BMI threshold | Same (≥30, or ≥27 with comorbidity) | Same (≥30, or ≥27 with comorbidity) |
| Step-therapy requirement (adults) | Yes (phentermine, benzphetamine, diethylpropion, or phendimetrazine) | Yes (same drugs) |
| OSA pathway | No — OSA is not an FDA-approved indication for Wegovy | Yes — separate OSA pathway, no step-therapy gate for that route |
| Oral tablet option | Yes (1.5 mg, 4 mg, 9 mg, 25 mg) — verify formulary status | No FDA-approved oral form |
For the parent view of every GLP-1 on TRICARE, see our TRICARE GLP-1 coverage hub.
Can You Use a Wegovy Savings Card or Coupon With TRICARE?
No. Novo Nordisk's published Wegovy savings card terms exclude patients enrolled in federal or state health-care programs with prescription drug coverage — including TRICARE, Medicare, Medicaid, VA, and DoD. The exclusion applies even when the beneficiary elects to self-pay and bypass their government insurance. Other GLP-1 manufacturer copay-assistance programs carry similar government-program exclusions.
If you've seen the “as little as $25 a month” Wegovy advertising — that's real, but only for patients on commercial (private) insurance that covers Wegovy. Three savings-card lanes:
| Lane | Who qualifies | Savings card outcome |
|---|---|---|
| Lane A | Commercial insurance that covers Wegovy | As little as $25/month with the savings card ✓ |
| Lane B | Commercial insurance doesn't cover Wegovy, or uninsured self-pay | NovoCare's published self-pay pricing, with eligibility conditions |
| Lane C | Government insurance: Medicare, Medicaid, VA, DoD, TRICARE | Savings offer not available, even when self-paying outside insurance ✗ |
Good news for covered Prime/Select beneficiaries
You don't need the savings card. If TRICARE approves your Wegovy, your $44 (Home Delivery brand-formulary) or $48 (network retail) copay is already lower than the typical commercial savings-card floor — even before factoring in the active duty, Prime Remote, and medically retired sponsor exceptions.
Harder news for TFL/excluded beneficiaries
You don't get the savings card path. Your real options are the Medicare GLP-1 Bridge, the Part D cardiovascular-risk indication if eligible, or a verified cash-pay route — see the cash-pay verification table above.
For the deep dive on every Wegovy savings-card lane, see our Wegovy Savings Card 2026 guide.
What to Bring to Your TRICARE Provider Appointment
The single highest-leverage thing you can do for a clean approval is walk into your appointment with a complete documentation packet. Print this list. Highlight what you don't have yet. Get the missing items into your medical record before your PA visit, not after a denial.
| Document | Why it matters |
|---|---|
| Sponsor ID / DEERS info | Required on the PA form |
| Plan name (Prime / Select / Reserve Select / etc.) | Wrong plan code = wrong denial |
| Current height, weight, BMI (date measured) | Gate 4 |
| Baseline weight (six-plus months ago) | Renewal tracking |
| Obesity / overweight diagnosis | Gate 2 (indication) |
| Comorbidity documentation (if BMI 27–29.9) | Gate 4 |
| Six-month behavioral/dietary modification record | Gate 5 — most common denial reason |
| Prior step-therapy drug history (phentermine, etc.) — dates, dose, weight response | Gate 6 |
| Contraindication documentation (if applicable) | Gate 6 exception |
| Adverse-reaction documentation (if applicable) | Gate 6 exception |
| Pregnancy status | Safety stop |
| Current GLP-1 medication (if any) | Safety stop |
| Personal/family MTC or MEN2 history | Safety stop |
| Preferred pharmacy channel | Refill planning |
| Renewal goal tracking plan (5% adult / 4% pediatric) | Year 2 planning |
How We Verified This Guide
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We don't take payment from manufacturers, insurance companies, or government agencies. Our affiliate relationships with Ro and Sesame Care are disclosed in every commercial section. Primary sources verified the week of May 15, 2026:
| Source | What we checked |
|---|---|
| TRICARE.mil — Does TRICARE cover Wegovy, Ozempic, and Mounjaro? FAQ | Covered plans, excluded groups, diabetes vs weight-loss distinction |
| TRICARE.mil — Weight Loss Products policy page | August 31, 2025 policy change; eligible vs excluded plan list |
| TRICARE.mil — Pharmacy Costs (updated April 10, 2026) | 2026 copays for active duty, Prime Remote, medically retired, and other beneficiaries |
| TRICARE.mil — Pharmacy Appeals | Written appeal requirement, 90-calendar-day window |
| Express Scripts — TRICARE Pharmacy Program GLP-1 FAQ | Provider requirements; pharmacy channel rules |
| Express Scripts — TRICARE Wegovy/Zepbound PA form (current revision) | Decision-tree questions, BMI thresholds, step-therapy drug list, comorbidity list, safety stops, renewal criteria |
| MOAA — TFL weight-loss coverage advocacy (2025–2026 articles) | TFL exclusion context; beneficiary testimony; Col. Fivehouse legal-case reporting |
| CMS — Medicare GLP-1 Bridge program guidance | July 1, 2026 launch; eligible products; $50 copay; PA criteria |
| FDA — Wegovy prescribing information | Indications, contraindications, dosing, MTC/MEN2 label restriction |
| FDA press announcement (March 19, 2026) | Wegovy HD 7.2 mg approval |
| Reuters — STEP UP trial results | 20.7% vs 17.5% mean body-weight loss comparison |
| NovoCare — Wegovy savings card terms | Government-beneficiary exclusion language |
| Ro.co — Body membership insurance policy | TRICARE beneficiary cash-pay membership language |
| Sesame Care — public program pricing and Terms of Service | Program pricing and federal-program eligibility language |
This page is informational. It is not medical advice, benefits advice, or a coverage determination. Talk to your prescriber and to Express Scripts (1-877-363-1303) before making decisions about your Wegovy treatment or coverage path.
Frequently Asked Questions
Does TRICARE Prime cover Wegovy?
Yes. TRICARE Prime covers Wegovy for weight management when the patient meets clinical criteria and a TRICARE Network or MTF provider gets prior authorization approved. Active-duty service members pay $0; TRICARE Prime Remote beneficiaries also pay $0 in most channels; other Prime beneficiaries pay $44 for a 90-day brand-formulary supply through TRICARE Pharmacy Home Delivery.
Does TRICARE Select cover Wegovy?
Yes. TRICARE Select covers Wegovy for weight management under the same prior-authorization criteria as TRICARE Prime. The 2026 brand-formulary copay is $44 for a 90-day Home Delivery supply or $48 for a 30-day supply at a network retail pharmacy.
Does TRICARE For Life cover Wegovy?
No. TRICARE For Life lost weight-loss GLP-1 coverage on August 31, 2025 under a Defense Health Agency regulatory-controls policy. Diabetes-indicated GLP-1s (Ozempic, Mounjaro, Trulicity, Victoza) remain covered for type 2 diabetes. TFL beneficiaries seeking Wegovy can check Medicare Part D coverage if eligible, the Medicare GLP-1 Bridge starting July 1, 2026, or a verified cash-pay path.
Does TRICARE Reserve Select cover Wegovy?
Yes. TRICARE Reserve Select is one of the premium-based plans eligible for Wegovy weight-management coverage with approved prior authorization. The most common Reserve Select denial reason is a PA-form plan-category coding error. If you're denied, call Express Scripts at 1-877-363-1303 to verify correct plan representation before resubmitting.
Does TRICARE cover the Wegovy pill (oral tablets)?
The current Express Scripts PA form is titled for semaglutide injection and tablets, but the pediatric pathway explicitly limits coverage to Wegovy injection for ages 12–17. Adult tablet coverage should be verified directly in the live TRICARE Formulary Search Tool before your appointment, as SKU-level status can change with quarterly formulary updates.
Does TRICARE cover Wegovy HD (7.2 mg)?
Wegovy HD was FDA-approved on March 19, 2026. Its TRICARE formulary status should be verified directly in the live TRICARE Formulary Search Tool. If approved as a non-formulary medical-necessity request, the Home Delivery copay would be $85 for a 90-day supply under standard non-active-duty pricing.
What BMI do I need for Wegovy with TRICARE?
Adults need a BMI of 30 or higher, or a BMI of 27 to 29.9 with at least one listed weight-related comorbidity (type 2 diabetes, OSA, osteoarthritis, metabolic syndrome, dyslipidemia, hypertension, MASH, or established cardiovascular disease). Adolescents 12–17 need a BMI at or above the 95th percentile standardized for age and sex.
Do I have to try phentermine before Wegovy with TRICARE?
The current TRICARE Wegovy PA form's adult step-therapy gate requires a documented three-month trial of phentermine, benzphetamine, diethylpropion (IR or SR), or phendimetrazine (IR or SR) that failed to produce 5% baseline weight loss — OR a documented contraindication or adverse reaction to those four drugs. Only those four drugs satisfy the step-therapy gate. The pediatric pathway does not have a step-therapy gate.
How long does TRICARE Wegovy approval last?
Initial therapy approval is for 12 months. Renewal requires continued behavioral modification and reduced-calorie diet, plus at least 5% baseline body-weight loss after full titration to 2.4 mg for adults, or 4% baseline weight loss for adolescents 12–17.
Can I use a Wegovy savings card with TRICARE?
No. Novo Nordisk's published Wegovy savings card terms exclude patients enrolled in federal or state health-care programs with prescription drug coverage, including TRICARE. The exclusion applies even if you offer to self-pay and bypass your TRICARE benefit. Your TRICARE Home Delivery brand-formulary copay ($44 for 90 days for most non-active-duty beneficiaries) is already lower than the savings-card $25/month floor.
Will TRICARE cover Wegovy for cosmetic weight loss?
No. TRICARE has never approved GLP-1 coverage for cosmetic weight loss. The PA form requires documented obesity or overweight with a qualifying comorbidity, documented lifestyle attempts, and step therapy. Cosmetic-intent requests are denied at the indication gate.
Can I get Wegovy from a base pharmacy?
Yes, if your PA is approved and the MTF pharmacy stocks Wegovy. Military pharmacies generally don't keep non-formulary drugs in stock unless a medical-necessity authorization is on file. Call your MTF pharmacy before walking in. If they don't have it, TRICARE Pharmacy Home Delivery is your $0 (active duty / Prime Remote) or $44 (90-day brand-formulary) backup.
Can a telehealth provider submit my TRICARE Wegovy PA?
Only if the telehealth provider is a TRICARE Network or MTF provider who has billed TRICARE for professional services to assess you and develop a treatment plan. A cash-pay telehealth doctor writing a prescription without TRICARE Network status will not unlock TRICARE coverage, even if the prescription itself is valid.
What happens to my Wegovy coverage if I transition from active duty to TRICARE For Life?
Your Wegovy weight-loss coverage ends at the transition. TFL has not covered weight-loss GLP-1s since August 31, 2025. If you have established cardiovascular disease, your Part D plan may cover Wegovy under its cardiovascular-risk indication. Starting July 1, 2026, the Medicare GLP-1 Bridge program will cover Wegovy at a $50 monthly copay for eligible Medicare Part D beneficiaries who meet the Bridge's PA criteria.
Does USFHP cover Wegovy?
Yes. The US Family Health Plan (USFHP) is one of TRICARE's eligible plan categories for Wegovy weight-management coverage with prior authorization. USFHP regions operate their own pharmacy networks and may use region-specific PA workflows. Verify the correct PA process with your USFHP designated provider or plan before submitting.
Still Figuring Out Your Path?
Take our free 60-second matching quiz. We'll account for your TRICARE plan, BMI, comorbidities, step-therapy history, and whether you want injection or pill — and tell you the realistic best path for your situation. No spam. No sign-up wall.
Take the 60-Second GLP-1 Match Quiz →TFL or excluded? Explore cash-pay GLP-1 options with Ro Body
Ro Body membership ($39 first month, $149/month ongoing, or ~$74/month with annual plan) allows TRICARE beneficiaries to pay cash for certain cash-pay medication options. Government-insurance coordination is not available. Confirm Wegovy availability for TRICARE users directly with Ro before signing up.
Check Ro Cash-Pay GLP-1 Options → (sponsored affiliate link, opens in a new tab)Sponsored affiliate link. We may earn commission. Coverage findings on this page are independent of affiliate relationships.